- Home
- PBHC vs IMAB Comparison
PBHC vs IMAB Comparison
Compare PBHC & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- IMAB
- Stock Information
- Founded
- PBHC 1859
- IMAB 2014
- Country
- PBHC United States
- IMAB United States
- Employees
- PBHC N/A
- IMAB N/A
- Industry
- PBHC Major Banks
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PBHC Finance
- IMAB Health Care
- Exchange
- PBHC Nasdaq
- IMAB Nasdaq
- Market Cap
- PBHC 92.1M
- IMAB 73.9M
- IPO Year
- PBHC N/A
- IMAB 2020
- Fundamental
- Price
- PBHC $14.74
- IMAB $1.28
- Analyst Decision
- PBHC
- IMAB Strong Buy
- Analyst Count
- PBHC 0
- IMAB 2
- Target Price
- PBHC N/A
- IMAB $5.50
- AVG Volume (30 Days)
- PBHC 7.7K
- IMAB 239.7K
- Earning Date
- PBHC 07-28-2025
- IMAB 05-15-2025
- Dividend Yield
- PBHC 2.58%
- IMAB N/A
- EPS Growth
- PBHC N/A
- IMAB N/A
- EPS
- PBHC 0.53
- IMAB N/A
- Revenue
- PBHC $41,317,000.00
- IMAB N/A
- Revenue This Year
- PBHC N/A
- IMAB N/A
- Revenue Next Year
- PBHC N/A
- IMAB N/A
- P/E Ratio
- PBHC $28.85
- IMAB N/A
- Revenue Growth
- PBHC 1.46
- IMAB N/A
- 52 Week Low
- PBHC $12.30
- IMAB $0.60
- 52 Week High
- PBHC $19.86
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- PBHC 43.79
- IMAB 73.09
- Support Level
- PBHC $14.85
- IMAB $0.90
- Resistance Level
- PBHC $15.64
- IMAB $1.47
- Average True Range (ATR)
- PBHC 0.42
- IMAB 0.10
- MACD
- PBHC 0.01
- IMAB 0.04
- Stochastic Oscillator
- PBHC 7.37
- IMAB 69.21
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).